Table 3.
Multivariate analyses of prognostic factors for 74 NSCLC patients with postoperative locoregional recurrence treated by radical radiotherapy
| Variable | OS | PFS | LRFS | DMFS | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Recurrence site (stump vs. regional lymph nodes vs. ipsilateral lung vs. multiple sites) | – | – | – | 1.421 (0.802–2.519) | 0.229 | |||
| BED of radiation (≥ 78 vs. < 78 Gy) | 0.472 (0.070–3.182) | 0.472 | – | 0.317 (0.112–0.899) | 0.031 | – | ||
| EGFR status (wild-type vs. mutation type vs. unknown) | 0.227 (0.034–1.498) | 0.118 | – | – | 0.383 (0.171–0.855) | 0.019 | ||
| Radiation technique (3D-CRT vs. IMRT vs. SBRT) | 4.406 (0.667–29.085) | 0.124 | – | 1.525 (0.516–4.503) | 0.445 | – | ||
OS overall survival, PFS progression free survival, LRFS local recurrence free survival, DMFS distant metastasis free survival, HR hazard ratio, CI confidence interval, BED biological effective dose, EGFR epidermal growth factor receptor, 3D-CRT 3-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, SBRT stereotactic body radiotherapy, GTV gross tumor volume, – not included